

Navidea to Host Moderated Q&A Webcast with Management

Webcast is scheduled with CFO Jed Latkin for Tuesday, February 13th at 5:00 p.m. ET

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today that it will hold an online Question & Answer (Q&A) Session with Jed Latkin, Chief Financial and Operating Officer, and Fred Cope, Ph.D., Chief Scientific Officer of Navidea, on Tuesday February 13, 2018 at 5:00 p.m. Eastern Time. Investors are invited to submit questions they would like to hear answered to ir@navidea.com or tpatel@edisongroup.com by Friday, February 9, 2018.

From time to time, between quarterly conference calls, the management will host Q&A webcasts so investors and potential investors can learn more about the Company, its strategy, and its products.

Event: Navidea Q&A Session – February 2018

Date: Tuesday, February 13th, 2018

Time: 5:00 p.m. Eastern
US/Canada Toll-Free: 800-239-9838
Conference ID: 9621939

Webcast: http://www.audio-webcast.com/cgi-bin/visitors.ssp?fn=visitor&id=5287

This ongoing Q&A series brings the Company closer to its shareholder base and is designed to maintain a continued open forum to highlight the Company's clinical trial progress as well as the many milestones Navidea hopes to achieve over the next several quarters.

For the February 13 Q&A Session, Navidea invites all interested investors to submit questions they would like to see asked by Friday, February 9 to ir@navidea.com or tpatel@edisongroup.com.

About Navidea Biopharmaceuticals:

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enabling better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea's Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc 99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. The development activities of the Manocept immunotherapeutic platform are being conducted by Navidea in conjunction with

its subsidiary, Macrophage Therapeutics, Inc. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company's pipeline through global partnering and commercialization efforts.

For more information, please visit http://www.navidea.com.

Forward Looking Statements:

This release and any oral statements made with respect to the information contained in this release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: general economic and business conditions, both nationally and in our markets; our history of losses and uncertainty of future profitability; the final outcome of the CRG litigation in Texas; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; our expectations and estimates concerning future financial performance, financing plans and the impact of competition; our ability to raise capital sufficient to fund our development and commercialization programs; our ability to implement our growth strategy; anticipated trends in our business; advances in technologies; and other risk factors set forth in this report and detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at www.sec.gov or at http://ir.navidea.com.

Investors are urged to consider statements that include the words "will," "may," "could," "should," "plan," "continue," "designed," "goal," "forecast," "future," "believe," "intend," "expect," "anticipate," "estimate," "project," and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180201006646/en/

Navidea Biopharmaceuticals, Inc. Jed Latkin, 614-973-7490 CFO/COO jlatkin@navidea.com or Edison Advisors Tirth Patel, 646-653-7035 tpatel@edisongroup.com

Source: Navidea Biopharmaceuticals, Inc.